We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > siltuximab

News List

EUSA Pharma launches phase III COVID-19 study for siltuximab pharmatimes
December 18, 2020
UK-headquartered EUSA Pharma has enrolled the first patient in a phase III study of siltuximab in patients hospitalised with COVID-19.
EUSA Pharma bags US approval for COVID-19 trial pharmatimes
July 03, 2020
US regulators have issued a green light for a Phase III clinical trial testing EUSA Pharma's for patients seriously ill with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).
Positive early data from siltuximab COVID-19 trial pharmatimes
April 02, 2020
A third of patients with COVID-19 taking EUSA Pharma's interleukin (IL)-6 targeted monoclonal antibody siltuximab have experienced a clinical improvement, according to early findings from an observational case-control trial in Italy.
Study evaluates if siltuximab benefits COVID-19 patients with respiratory complications europeanpharmaceuticalreview
March 23, 2020
The SISCO study will assess if the anti-IL-6 antibody siltuximab can aid patients suffering Acute Respiratory Distress Syndrome as a complication of the COVID-19 coronavirus.